NCT03815617View on ClinicalTrials.gov

A Novel Formulation of Bifidobacterium Longum BB536 and Lactobacillus Rhamnosus HN001 With Vitamin B6 on IBS Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

February 1, 2017

Primary Completion Date

May 31, 2018

Study Completion Date

December 31, 2018

Conditions
Irritable Bowel Syndrome
Interventions
DIETARY_SUPPLEMENT

Zircombi

Twenty-five IBS patients (Rome IV criteria) (M:F= 8:17; age 48 yrs ± 11 SD) were enrolled and randomized to treatment or placebo in a a crossover randomized double-blind two-block placebo-controlled trial. Abdominal pain and bloating, intestinal habits, severity of disease, intestinal permeability, and intestinal microbiota were performed at the different time points.

DIETARY_SUPPLEMENT

Placebo

Given as comparable packets. Same duration.

Trial Locations (1)

70124

"Clinica Medica A. Murri, Department of Biomedical Sciences & Human Oncology, University of Bari Medical School", Bari

All Listed Sponsors
lead

University of Bari

OTHER

NCT03815617 - A Novel Formulation of Bifidobacterium Longum BB536 and Lactobacillus Rhamnosus HN001 With Vitamin B6 on IBS Patients | Biotech Hunter | Biotech Hunter